Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8
|
2 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.800 | 1.000 | 11 | 2011 | 2019 | ||||
Neoplastic Syndromes, Hereditary
|
6387 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 22 | 1987 | 2016 | ||||
Tietz syndrome
|
5 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 5 | 2011 | 2016 | ||||
WAARDENBURG SYNDROME, TYPE IIA
|
26 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 5 | 2011 | 2016 | ||||
Anteverted nostril
|
35 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
Attention deficit hyperactivity disorder
|
420 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
Constipation
|
57 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
Mild microcephaly
|
5 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
Moderate intellectual disability
|
94 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
Narrow face
|
6 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
Speech Disorders
|
7 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
Stereotypic Movement Disorder
|
26 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.700 | 1.000 | 4 | 2011 | 2016 | ||||
melanoma
|
515 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.100 | 1.000 | 13 | 2011 | 2019 | ||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
222 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.050 | 0.800 | 5 | 2011 | 2019 | ||||
Renal Cell Carcinoma
|
288 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.050 | 0.800 | 5 | 2011 | 2019 | ||||
Neoplasms
|
1644 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.040 | 1.000 | 4 | 2013 | 2017 | ||||
Benign melanocytic nevus
|
20 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.030 | 1.000 | 3 | 2014 | 2017 | ||||
Malignant Neoplasms
|
1641 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.030 | 0.667 | 3 | 2011 | 2014 | ||||
Melanocytic nevus
|
33 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.030 | 1.000 | 3 | 2014 | 2017 | ||||
Nevus
|
43 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.030 | 1.000 | 3 | 2014 | 2017 | ||||
Adrenal Gland Pheochromocytoma
|
50 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Carcinogenesis
|
355 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.010 | 1 | 2016 | 2016 | |||||
Cutaneous Melanoma
|
248 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Kidney Neoplasm
|
11 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Malignant neoplasm of pancreas
|
277 | 0.672 | 0.560 | 3 | 69964940 | missense variant | G/A | snv | 1.4E-03 | 1.6E-03 | 0.010 | 1 | 2014 | 2014 |